Astellas will transfer its manufacturing plant and business based in Meppel, the Netherlands to Delpharm. The definitive agreement will be executed after completing works council consultation and local legal and regulatory requirements.

This manufacturing plant, fully equipped with state-of-the-art technologies, employs 332 personnel who contribute to the production of medicines in solid forms.

The Meppel site holds most of the quality authorizations for exporting to the world, including FDA certification for the U.S.

With this additional site, Delpharm will strengthen its position in the Netherlands where the CDMO already owns one manufacturing site in Bladel and an injectable drug development center in Leiden.